HopeStage
Back to all studies
CompletedNCT04276259

Reward Learning and Rapid Improvement in Depression

About this titleRead the official source — NCT04276259
Medication studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
PittsburghSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 19, 2020
Recruitment status
Completed
Enrollment listed in the registry
120
Sponsor
Marta Peciña, MD PhD
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Device, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT04276259
Official title
Show the full official title

Neurocomputational Mechanisms of Mood Improvement

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Pittsburgh

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Marta Peciña, MD PhD.

Did this study involve medication?

Yes. The study involved medication, including Buprenorphine, Naltrexone, Oral Placebo and IM Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies